Literature DB >> 16193828

Statins: the case for higher, individualized starting doses.

Peter H Jones1.   

Abstract

If patients with hypercholesterolemia were started on higher doses of statins tailored to their lipid levels and risk, more of them would achieve their low-density lipoprotein cholesterol (LDL-C) goals, possibly leading to fewer cardiovascular events and deaths.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16193828     DOI： 10.3949/ccjm.72.9.811

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  3 in total

Review 1.  Practical use of the Framingham risk score in primary prevention: Canadian perspective.

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2011-04       Impact factor: 3.275

2.  The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model.

Authors:  Andrew van Herick; C Andy Schuetz; Peter Alperin; Michael F Bullano; Sanjeev Balu; Sanjay Gandhi
Journal:  Clinicoecon Outcomes Res       Date:  2012-11-09

Review 3.  Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials.

Authors:  Furio Colivicchi; Catarina Sternhufvud; Sanjay K Gandhi
Journal:  Clinicoecon Outcomes Res       Date:  2015-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.